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Abstract Objective The aim of the current study was to evaluate quetiapine doses used
across diagnosis categories in a sample of psychiatric inpatients. Methods Discharge letters
of all adult inpatients who had received quetiapine between 1999 and 2005 were retro-
spectively reviewed. Logistic regressions were carried-out to assess links between
quetiapine discharge dosage (C800 mg/day vs. \800 mg/day), diagnostic categories,
substance abuse or dependence, benzodiazepine discharge doses, age and sex. Results The
data of 231 patients were included. Five hundred and for discharge documents were
analyzed: 113 for psychotic disorders, 190 for personality disorders, 134 for bipolar and
schizoaffective bipolar disorders, 29 for unipolar depression or anxiety disorders, and 35
for mental retardation. Considering psychotic disorders as a reference group, patients with
personality disorders were statistically significantly less likely to be in the high quetiapine
dosage group at discharge (P = 0.007, OR = 0.1 and CI [0.03; 0.6]). Conclusions
Quetiapine seems to be used in a variety of clinical situations, with a wide range of doses
and a lower dosage in patients treated for personality disorders.
Keywords Quetiapine  Antipsychotic drugs  Bipolar disorder  Schizophrenia 
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Introduction
Quetiapine is a novel antipsychotic drug labeled for the treatment of patients with
schizophrenia [1], bipolar mania [2] and bipolar depression [3].
The registration studies of quetiapine suggest a target dose of quetiapine ranging from
300 to 500 mg/day for schizophrenia, and a maximum dosage up to 800 mg/day [4].
Quetiapine has been tried across multiple diagnosis categories and seems to be used,
among other atypical antipsychotics, in clinical practice for an expanding range of
disorders [5].
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Several recent studies have demonstrated quetiapine’s clinical benefits in patients with
depression, impulsivity, aggression, and substance abuse disorders [6–10].
Preliminary works suggest interest of quetiapine in monotherapy or augmentation
strategy for a wide range of other psychiatric disorders such as antisocial personality
disorder (600–800 mg/day) [11], borderline personality disorders (175–400 mg/day) in
one study [12] and at higher dosage in a recent one (400–800 mg/day, with average daily
dosage: 540 mg/day) [13], resistant depression (mean dosage: 166.67 ± 211.69 mg/day)
[14], post traumatic stress disorders [15] (mean dosage: 216 mg/day), resistant obsessive
compulsive disorders (quetiapine dosages titrated upward to 300 mg/day, mean dose:
215 ± 124 mg/day) [16]. Controversial data, for example, on the lack of efficacy of
quetiapine at dosage lower than 150 mg/day highlights the importance of a precise
determination of the potentially effective dosage [17].
Whereas most validation studies on the efficacy of quetiapine used up to a maximum
dosage of 800 mg/day, naturalistic reports show a current use in higher dosage in a variety
of clinical situations [4, 18, 19]. Due to this gap between validation studies (quetiapine
used up to 800 mg/day) and naturalistic reports (quetiapine frequently used at higher doses
than 800 mg/day), the aim of the current retrospective study was to evaluate prescription of
quetiapine in dosage \800 mg/day and C800 mg/day across diagnostic categories in a
naturalistic sample of psychiatric inpatients.
Methods
All patients described in this retrospective cross-sectional descriptive study had been
treated in the Psychiatric hospital of the University Hospital of Vaud, Lausanne, Swit-
zerland. Discharge letters of all adult inpatients who had received a prescription for
quetiapine during at least one hospitalization (during the stay in the hospital and/or at
discharge) between December 1999 (introduction of quetiapine in Switzerland) and Sep-
tember 2005 were retrospectively reviewed. Discharge letters are the official and final
medical document, signed by a resident in psychiatry and a senior psychiatrist, which
summarize events, diagnosis, symptoms evolution and treatment during hospitalization and
contains systematic reporting of all treatments at discharge. Discharge letters containing
the word quetiapine were identified through a computerized research. Letters that did not
contain this word were not checked. Letters in which quetiapine was not reported at
discharge were excluded from the analysis.
The following information was recorded from the discharge letter: baseline demo-
graphic characteristics, psychiatric diagnostic including active substance abuse or
dependence, number of previous hospitalization, medication including benzodiazepine
dosage at discharge (in lorazepam equivalent), quetiapine dose at discharge, duration of
hospitalization, civil compulsory hospitalizations. Diagnoses were established according to
DSM-IV criteria by the residents in psychiatry and senior psychiatrists.
The presented data are drawn from a study protocol approved by the local Ethical
committee and the institutional review board.
Analyses
Statistical analyses were carried out using SPSS for Windows (version 11.0).
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An initial exploratory analysis involved calculation of means, standard deviation and
median for age and discharge quetiapine and benzodiazepine (in lorazepam equivalent)
dosages.
Diagnostic categories are regrouped in 5 categories as follows:
(1) Bipolar spectrum including: bipolar disorder and schizoaffective bipolar disorder in
manic or mixed states (with exclusion of bipolar depression due to small sample size: 6
discharge letters), (2) Psychotic disorders including: schizophrenia and schizoaffective
disorders depressive type, psychotic disorders not otherwise specified, delusional disorders,
(3) Unipolar depression and anxiety disorders, (4) Personality disorders (cluster B), (5)
Mental retardation.
Schizoaffective disorder, bipolar type and bipolar disorder were in the same category
‘‘Bipolar spectrum’’ in accordance with previous results [19] showing that higher quetia-
pine dosage is rather related to the mood episode type than to the category of bipolar
disorder or schizoaffective bipolar disorder.
When co-morbidity was mentioned, the categorization was considered in consideration
of the diagnosis linked to the hospitalization as reported in the discharge letter. Substance
abuse or dependence was considered as, a co-morbidity.
Quetiapine doses between diagnostic categories were studied in consideration of high
(C800 mg/day) vs. low (\800 mg/day) quetiapine dosage repartition, in consideration to
the 800 mg cut-off of validation studies and the frequency of prescription of doses higher
than 800 mg/day in clinical practice.
Analyses were conducted on the sample of patients, taking the mean quetiapine dose
over all the hospitalizations made by each patient (the average of the different daily
discharge dose prescribed for each patient). The mean quetiapine doses as the dependent
variable of age, benzodiazepine discharge doses, diagnostic categories, sex, as well as
substance abuse variables as predictors were tentatively analyzed through a multiple linear
regression. Because of strong deviance from normality and non-constant variance, the data
were finally analyzed by a logistic regression model providing a better fit. The mean
quetiapine discharge dose was categorized into high dose: C800 mg vs. low dose:
\800 mg/day. Goodness of fit of the model was assessed through the logarithm of the
likelihood and the Nagelkerke R2 statistics. Leverage values were also analyzed for
detecting cases that have a large impact on the predicted values. For all analyses, a
significance level of P B 0.05 was used.
Results
Five hundred and four discharge letters were analyzed after exclusion of 38 discharge
letters of patients who were not discharged with quetiapine (refusal of treatment, switch, to
another antipsychotic agent, quetiapine side effects, considering no reason for quetiapine
maintenance treatment). The data of 231 patients [female (59%)], were included into the
analyses. During the studied period the included patients totalized 504 hospitalizations:
113 hospitalizations for psychotic episodes, 190 for personality disorders (cluster B), 137
for bipolar and schizoaffective bipolar disorder, 29 for unipolar depression [15] or anxiety
disorder [14] and 35 for mental retardation. Only three patients (7 hospitalizations)
received quetiapine for two different diagnoses in successive hospitalizations, the last
diagnosis was considered for each of these patients because it was considered as more
accurate by the clinicians. Forty-three percent of the study sample had a co-morbidity of
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substance abuse or dependence to one or more substances, most frequently alcohol (50%),
marijuana (40%), cocaine (15%) and opiate (4%).
The socio-demographic and clinical characteristics of the patients and the hospital-
izations are shown in Table 1. The logistic regression performed well with an overall
percentage of 85% of the cases correctly classified (high: C800 mg/day vs. low:
\800 mg/day quetiapine dosage category). The R2 Nagelkerke statistics show that about
67% of the variation in the outcome variable is explained by the logistic regression
model. The variables, age and diagnosis, are statistically significant (P \ 0.0005 and
P = 0.002 respectively) while benzodiazepine dosage, sex and substance abuse or
dependence are not. Compared to those with psychotic disorders (Table 2), patients with
personality disorders were significantly less likely to be in the high dose category
(P = 0.007, OR = 0.1 and CI [0.03; 0.6]). Considering age variable, an increase of
1 year decreases the likelihood to be in the high quetiapine dose group (P \ 0.0005,
OR = 0.96 and CI [0.93; 0.98]).
Table 1 Sociodemographic and clinical characteristics (the reported diagnosis is the diagnosis linked to the
hospitalization)
Patients (n) 231
Female (%) 59%
Age, years (mean ± SD; median) 36.3 ± 11.3; 35
Numbers of previous hospitalization (mean ± SD; median) 7.4 ± 11.3; 4
Daily mean quetiapine dosage 393.8 ± 320.2
Mean quetiapine dosage by episode
(1) Psychotic disorders 557.3 ± 277.5
(2) Bipolar disorders and schizoaffective, bipolar type 435 ± 395.4
(3) Personality disorders 251.6 ± 211.7
(4) Depressive and anxiety disorders 279.2 ± 279.9
(5) Mental retardation 414.2 ± 223
Number of subjects by episode type (n)
(1) Psychotic disorders 58
(2) Bipolar disorders and schizoaffective, bipolar type 69
(3) Personality disorders 74
(4) Depressive and anxiety disorders 18
(5) Mental retardation 12
Hospitalizations (n) 504
Number of hospitalizations during the studied period (mean ± SD) 1.9 ± 1.6
Actual comorbidity with a substance abuse or dependence (%) 216, 43%
Bipolar disorders and schizoaffective, bipolar type (n, %) 137, 27.2%
Personality disorders (n, %) 190, 37.7%
Psychotic disorders (n, %) 113, 22.4%
Depressive and anxiety disorders (n, %) 29 (5.8%)
Mental retardation (n, %) 35 (6.9%)
Duration in days (mean ± SD; median) 19.3 ± 22.8; 10
Civil compulsory hospitalization (%) 22%
Quetiapine discharge dosage in mg/day (mean ± SD; median) 427.6 ± 316.2; 400
Doses C800 mg/day at discharge (n, %) 73 (14.5%)
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Discussion
In accordance with previous naturalistic studies [5], it seems that quetiapine is given
commonly in off-label as well as in labeled indication for the treatment of a large range of
psychiatric disorders. The main finding of this study is that the use of quetiapine discharge
doses (\800 vs. C800 mg/day) is clearly influenced by diagnostic categories whereas
benzodiazepine discharge dosage, co-morbid substance abuse or dependence did not
contribute significantly to the final model. Personality disorders are less likely than psy-
chotic disorders to need quetiapine dosage at discharge higher than 800 mg/day. Clinical
differences across diagnostic categories could explain the finding, however one could
hypothesize that clinicians are more likely to dose above licensed doses for licensed
indications but not for unlicensed indications. Interestingly, the study found a link between
age and quetiapine discharge doses. This may be due to differences of symptomatology
between younger and older people or to a poorer tolerance of higher dosage in older
patients. We excluded only 38 discharge letters of patients who were not discharged with
quetiapine. Whereas all discharge letters are expected to mention all treatments used
during a hospitalization, it is possible that discharge letters may have failed to mention a
quetiapine administration.
Some limitations have to be considered when interpreting the results of the present
study. Especially, its open-label retrospective design, lack of prospective outcome mea-
sures, and the observation limited to the discharge period.
The result suggests the need for conducting prospective randomized controlled trials
(with flexible or with multiple fixed doses including dosage higher than 800 mg/day) in
order to assess efficacy and optimal doses of quetiapine in various psychiatric disorders
such as unipolar depression, anxiety disorders, personality disorders, bipolar disorders and
schizophrenia.
Conclusion
Quetiapine is used in a variety of clinical situations, in a wide range of doses, with a lower
dosage for patients treated for a personality disorder.
Table 2 Odds ratio to receive quetiapine at dosage C800 mg/day at discharge (for diagnostic variable,
psychotic disorders is the reference group)
Variable OR 95% CI P-value
Age 0.96 0.93–0.98 \0.0005
Benzodiaze´pine dosage 1.07 0.98–1.16 0.1
Substance abuse/dependence 0.6 0.2–1.3 0.2
Gender 1.003 0.44–2.27 0.9
Diagnostic – – 0.002
Psychotic disorders 1 – –
Bipolar disorder spectrum 2.3 0.9–5.8 0.09
Unipolar depression and anxiety disorders 0.3 0.03–2.7 0.3
Personality disorders 0.1 0.03–0.6 0.007
Mental retardation 0.3 0.03–2.7 0.3
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